Endoscopic Sleeve Gastroplasty for Moderate Obesity

Weight loss is of paramount importance to ameliorate obesity-related complications. Endoscopic sleeve gastroplasty is a new therapeutic option to obtain significant weight reduction in obese patients. Nevertheless, a only a part of patients experience sufficient weight loss to improve comorbidities. A better understanding of mechanisms driving body weight trajectory after endoscopic sleeve gastroplasty may help patient selection and improve efficacy. The main aim of this study is to identify factors associated with weight reduction after endoscopic sleeve gastroplasty in patients with overweight or morbid obesity without indication to bariatric surgery. For this purpose, the investigators conduct a retro-prospective cohort study including patients with overweight or moderate obesity undergoing endoscopic sleeve gastroplasty between March 2017 and March 2023

Inclusion Criteria:Age ≥18 yearsPatients giving their consent for the studyBody mass index between 28 and 35 kg/m2 with co-morbid condition (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease or invalidating joint pain)No weigh loss following life-style changesExclusion Criteria:Antibiotic treatment during the three previous monthsPatients at risk of gastric cancer requiring regular endoscopic surveillanceGastric localization of Crohn diseasePortal hypertensionSevere hepatic or renal failureOngoing peptic ulcerSevere associated diseaseHistory of previous bariatric surgery